Navigation Links
BBK Worldwide Celebrates 25th Anniversary of Industry Leadership Through Innovation in Patient Enrollment
Date:6/25/2008

ip product, TrialCENTRALNet(SM), which also serves as the technology backbone. TrialCENTRALNet provides an online infrastructure for planning, conducting and managing patient recruitment, instantly centralizing all related communications, data, reporting, and information for a single clinical study, or a suite of studies.

"Through our hands-on experience with hundreds of clinical trials, we've learned that it's not a matter of spending more time on recruitment; it's about recognizing patient recruitment as a distinct discipline and giving all study community members access to its principles," says Bachenheimer. "BBK's current initiatives are designed to do just that."

BBK and TCN e-Systems will showcase "Center of Excellence" and QuickTrainer at the 44th Annual Meeting of the Drug Information Association in Boston from June 22 - 26, 2008 at booth #711.

About BBK Worldwide

Founded in 1983 by Joan F. Bachenheimer and Bonnie A. Brescia, BBK Worldwide is a patient recruitment and e-business solution company for the clinical R&D and product marketing segments of the pharmaceutical, biotechnology, and medical device industries. BBK has helped to accelerate time to market for new medicines and treatments by successfully supporting hundreds of clinical studies in more than 60 countries, and in all major therapeutic areas. Staffed by some of the industry's principal thought leaders, BBK continually contributes ideas that advance the clinical development cycle. (http://www.bbkworldwide.com)

About TCN e-Systems, LLC

TCN e-Systems, located in Newton, Mass., is an e-recruitment company focused on streamlining patient enrollment for life-sciences companies through Web-based product suites that are designed to respond to the six enrollment risk areas. Founded in October 2006 by Joan F. Bachenheimer and Bonnie A. Brescia, also founding principals of industry-leading patient recruitment
'/>"/>

SOURCE BBK Worldwide
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orion Genomics Gains Exclusive Worldwide Rights to the IGF2 Gene for Colorectal Cancer Risk Testing Through Licensing Agreement With Johns Hopkins University
2. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
3. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
7. Getty Images Celebrates Conclusion of Change Me Imagery Forum
8. Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
9. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
10. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 2007 /PRNewswire-FirstCall/ -- Celgene,Corporation announced that the ... its Data Monitoring Committee's (DMC),review of preliminary ... patients with newly diagnosed multiple myeloma has ... of dexamethasone (Decadron) in,combination with lenalidomide suggests ...
... HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. ... an important,pilot study with a novel synDNA(TM) ... protect against the avian (H5N1),influenza virus. The ... mice treated with the Company's synDNA(TM) vaccine,whereas ...
Cached Medicine Technology:ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus 2
(Date:9/1/2014)... September 01, 2014 An operating theatre ... hospital for performing surgical operations. An operating room comprises ... surgical booms, operating room lights, imaging displays as well ... report by Transparency Market Research, a U.S.-based market research ... reach USD 4.5 billion by 2019. , According ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, 2014 (HealthDay ... American aid workers successfully cured a group of monkeys infected ... The drug, ZMapp, prompted recovery in all 18 monkeys who ... five days after infection. ZMapp even cured monkeys with ... away from death, said study senior author Gary Kobinger, chief ...
(Date:9/1/2014)... The National Association of Hispanic Nurses ... Bazarko, DNP, MPH, RN, and Adriana Perez, PhD, Rn, ... of Nursing. They will be inducted with Immediate Past ... induction we reported last May. , Our three members ... 2014 American Academy of Nursing Policy Conference in Washington, ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... , TUESDAY, Jan. 17 (HealthDay News) -- Middle-aged men ... risk for atrial fibrillation later in life, researchers say. ... Americans -- is a heart rhythm disorder that can lead ... a known risk factor for atrial fibrillation. Previous research ...
... Centre today performed a minimally invasive surgical procedure to ... first time in Canada. The procedure can significantly reduce ... their hypertension through drugs. These patients, numbering approximately 250,000 ... heart attacks and stroke, which continues to kill thousands ...
... at Kessler Foundation have documented increased cerebral activation ... retraining using the modified Story Memory Technique (mSMT). ... behavioral interventions can have a positive effect on ... validating the clinical utility of cognitive rehabilitation. According ...
... By Kathleen Doheny HealthDay Reporter , ... that target an aggressive type of breast cancer known ... drug alone, researchers report. The dual-drug approach greatly ... cancer by the time a woman was due to ...
... treatment of large tumors, how effective is adoptive T ... answer this question, Dr. Kathleen Anders and Professor Thomas ... (MDC) Berlin-Buch and researchers of the Beckman Research Institute ... California, USA designed and carried out a study comparing ...
... If organisations want to retain qualified nurses they need to ... three key age groups and build on the strong attachment ... key messages to emerge from a large-scale survey of nurses ... Advanced Nursing . Australian researchers surveyed 900 nurses from ...
Cached Medicine News:Health News:'Upper Normal' Blood Pressure Linked to Heart Risk in Men 2Health News:Canada's first renal denervation procedure to reduce high blood pressure performed today 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 2Health News:Drug Duo May Help Fight Aggressive Form of Breast Cancer 3Health News:How immune cells destroy cancer cells - MDC researchers elucidate mechanism 2Health News:Retention study identifies key factors affecting 3 generations of nurses 2Health News:Retention study identifies key factors affecting 3 generations of nurses 3
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: